FDA panel votes no on general public COVID-19 booster dose: What that means

The FDA’s vaccine advisory committee has voted against a generally available third Pfizer COVID-19 booster, though left alternative routes open for other high-risk individuals. The panel, comprised of independent public health and scientific experts, pushed back at suggestions that sufficient data of vaccine safety had been gathered. The Vaccines and Related Biological Products Advisory Committee is a non-binding committee, and …